SCHEMBL16797233

SCHEMBL16797233

COc1ccc(Cn2nc(C(=O)c3c(Cl)cccc3Cl)c3cccnc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
THRB P10828 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.48
LMNA P02545 1/20 0.45
PPARG P37231 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
PTGER4 P35408 2/20 0.43
NPBWR1 P48145 1/20 0.41
TP53 P04637 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
ALOX15 P16050 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18205767 0.91 RORC (0.46) MAPTTHRBPTGDR2LMNAPPARG
SCHEMBL28098679 0.90 PTGDR2 (0.54) MAPTTHRBPTGDR2LMNAPPARG
SCHEMBL18205764 0.90 MAPT (0.44) MAPTTHRBPTGDR2LMNAPPARG
SCHEMBL10126774 0.85 PTGDR2 (0.53) MAPTTHRBPTGDR2LMNAL3MBTL1
SCHEMBL16797158 0.84 PTGER4 (0.59) L3MBTL1PTGER4CNR1CNR2ALOX15
SCHEMBL9925002 0.84 PTGDR2 (0.52) MAPTTHRBPTGDR2LMNAL3MBTL1
SCHEMBL13347985 0.84 PTGDR2 (0.54) MAPTTHRBPTGDR2LMNAL3MBTL1
SCHEMBL28007646 0.83 PTGDR2 (0.51) MAPTTHRBPTGDR2LMNAL3MBTL1
SCHEMBL16797249 0.81 MEN1 (0.43) L3MBTL1PTGER4TP53ALOX15RXFP1
SCHEMBL9925003 0.81 PTGDR2 (0.54) MAPTTHRBPTGDR2LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080090-B1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2018-01-31 EP disclosed
US-9682977-B2 Bicyclic heteroaryl indole analogues useful as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2017-06-20 US disclosed
US-20160326163-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2016-11-10 US disclosed
EP-3080090-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2016-10-19 EP disclosed
WO-2015087234-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326163-A1 BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS RORA, RORB, RORC MAPT 958/4885THRB 175/4885PTGDR2 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.